{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:28:20Z","timestamp":1787063300307,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260130"],"award-info":[{"award-number":["82260130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260130"],"award-info":[{"award-number":["82260130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260130"],"award-info":[{"award-number":["82260130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260130"],"award-info":[{"award-number":["82260130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260130"],"award-info":[{"award-number":["82260130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260130"],"award-info":[{"award-number":["82260130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["20224BAB206021"],"award-info":[{"award-number":["20224BAB206021"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["20224BAB206021"],"award-info":[{"award-number":["20224BAB206021"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["20224BAB206021"],"award-info":[{"award-number":["20224BAB206021"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["20224BAB206021"],"award-info":[{"award-number":["20224BAB206021"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["20224BAB206021"],"award-info":[{"award-number":["20224BAB206021"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["20224BAB206021"],"award-info":[{"award-number":["20224BAB206021"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The incidence and mortality of hepatocellular carcinoma are still high according to National Cancer Center of China. Atezolizumab plus bevacizumab has become one of the standard regimens for the first-line treatment of unresectable hepatocellular carcinoma. However, some patients still use lenvatinib in combination with immunotherapy instead of a standard \u201catezolizumab-bevacizumab\u201d regimen as a lower risk of bleeding in patients with esophagogastric varices. However, there is no evidence for second-line therapy after progression on lenvatinib combined with PD-1 inhibitor in unresectable hepatocellular carcinoma till now. Herein, we aim to investigate second-line treatment among these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Thirty-three patients with unresectable hepatocellular carcinoma with esophagogastric varices were admitted to the Second Affiliated Hospital of Nanchang University from January 2019 to December 2023. They were treated with lenvatinib in combination with PD-1 inhibitor as first line. The efficacy was conducted according to the RECIST1.1 criteria. The endpoints included objective response rate (ORR), disease control rate (DCR), median overall survival (OS), and median progression free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified a total of 225 patients with unresectable hepatocellular carcinoma with esophagogastric varices who received first-line lenvatinib in combination with PD-1 inhibitor, of whom 33 (14.7%) received second-line therapy. 21 patients (63.6%) were treated with regorafenib combined with PD-1 inhibitor, 6 patients (18.2%) with apatinib plus PD-1 inhibitor, 4 patients (12.1%) with bevacizumab plus PD-1 inhibitor, and the remaining 2 patients with regorafenib or sorafenib as monotherapy, respectively. Of the 33 patients, 2 (6.1%) were evaluated as partial response (PR), 16 (48.5%) had stable disease (SD), and 15 (45.4%) experienced progression (PD). The ORR was 6.1%, and the DCR was 54.6%. Median PFS was 4.5 months, median OS was 7.2 months, and the 12-month OS rate was 27.3%. Overall survival follow-up was done in 37 patients without second line treatment whose baseline levels were matched with those of the treatment group. The OS was 7.2 months in second line treatment group versus 3.0 months in control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). As for different treatments in a second line, The ORR of regorafenib in combination with PD-1 inhibitor was 9.5%, the DCR was 47.6%, the median PFS was 4.2 months, and the median OS was 5.9 months. None of the patients treated with apatinib plus PD-1 inhibitor got PR, the DCR was 83.3%, the median PFS was 8.7 months, and the median OS was 9.1 months. None of the patients treated with bevacizumab plus PD-1 inhibitor got PR, the DCR was 25.0%, the median PFS was 2.2 months, and the median OS was 6.0 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor is effective. Regorafenib or apatinib combined with PD-1 inhibitor might be the preferred options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-025-03742-0","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:51:18Z","timestamp":1741848678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor"],"prefix":"10.1186","volume":"23","author":[{"given":"Saifeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"3","key":"3742_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin May. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin May"},{"issue":"3","key":"3742_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol Mar. 2022;76(3):681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol Mar"},{"issue":"20","key":"3742_CR3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"14","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. May 2020;14(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"issue":"26","key":"3742_CR4","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/jco.20.00808","volume":"10","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol Sep. 2020;10(26):2960\u201370. https:\/\/doi.org\/10.1200\/jco.20.00808.","journal-title":"J Clin Oncol Sep"},{"issue":"12","key":"3742_CR5","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/s1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol Dec. 2023;24(12):1399\u2013410. https:\/\/doi.org\/10.1016\/s1470-2045(23)00469-2.","journal-title":"Lancet Oncol Dec"},{"key":"3742_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/itt.S452339","volume":"13","author":"WB Duan","year":"2024","unstructured":"Duan WB, Wang XH, Zhang GC, He Z, Li SQ, Zhou J. Efficacy of lenvatinib combined with PD-1 inhibitor versus Sorafenib and PD-1 inhibitor with or without TACE for hepatocellular carcinoma with extrahepatic metastasis. Immunotargets Ther. 2024;13:247\u201358. https:\/\/doi.org\/10.2147\/itt.S452339.","journal-title":"Immunotargets Ther"},{"issue":"1","key":"3742_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3892\/ol.2024.14445","volume":"28","author":"B Zhang","year":"2024","unstructured":"Zhang B, Su L, Lin Y. Efficacy and safety of lenvatinib combined with PD\u20131\/PD\u2013L1 inhibitors in the treatment of hepatocellular carcinoma: A meta\u2013analysis and systematic review. Oncol Lett Jul. 2024;28(1):312. https:\/\/doi.org\/10.3892\/ol.2024.14445.","journal-title":"Oncol Lett Jul"},{"key":"3742_CR8","doi-asserted-by":"publisher","first-page":"175883592312062","DOI":"10.1177\/17588359231206274","volume":"15","author":"Q Liu","year":"2023","unstructured":"Liu Q, Li R, Li L, et al. Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience. Ther Adv Med Oncol. 2023;15:17588359231206274. https:\/\/doi.org\/10.1177\/17588359231206274.","journal-title":"Ther Adv Med Oncol"},{"key":"3742_CR9","doi-asserted-by":"publisher","unstructured":"Zhang W, Tong S, Hu B, et al. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial. J Immunother Cancer Sep. 2023;11(9). https:\/\/doi.org\/10.1136\/jitc-2023-007366.","DOI":"10.1136\/jitc-2023-007366"},{"issue":"1","key":"3742_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12957-024-03396-4","volume":"6","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhang H, Xu H, Wang Y, Feng L, Yi F. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion. World J Surg Oncol May. 2024;6(1):122. https:\/\/doi.org\/10.1186\/s12957-024-03396-4.","journal-title":"World J Surg Oncol May"},{"key":"3742_CR11","doi-asserted-by":"publisher","unstructured":"Ou X, Wu J, Wu J, et al. Efficacy of lenvatinib combined with Anti-PD-1 antibodies plus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A retrospective, multicenter study. Cancer Res Treat Apr. 2024;30. https:\/\/doi.org\/10.4143\/crt.2023.1165.","DOI":"10.4143\/crt.2023.1165"},{"key":"3742_CR12","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.2147\/jhc.S432542","volume":"10","author":"G Li","year":"2023","unstructured":"Li G, Zhao Y, Li K, et al. Effectiveness and safety of the PD-1 inhibitor lenvatinib plus radiotherapy in patients with HCC with main PVTT: Real-World data from a tertiary centre. J Hepatocell Carcinoma. 2023;10:2037\u201348. https:\/\/doi.org\/10.2147\/jhc.S432542.","journal-title":"J Hepatocell Carcinoma"},{"key":"3742_CR13","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.2147\/jhc.S426308","volume":"10","author":"Q Shi","year":"2023","unstructured":"Shi Q, Huang P, Zhang Z, Zhang W, Liu L, Yan Z. Hepatocellular carcinoma with radiological progression: lenvatinib plus PD-1 inhibitor combined with microwave ablation and synchronous transarterial chemoembolization. J Hepatocell Carcinoma. 2023;10:1861\u201371. https:\/\/doi.org\/10.2147\/jhc.S426308.","journal-title":"J Hepatocell Carcinoma"},{"issue":"10064","key":"3742_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/s0140-6736(16)32453-9","volume":"7","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on Sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Jan. 2017;7(10064):56\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(16)32453-9.","journal-title":"Lancet Jan"},{"issue":"7","key":"3742_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/s2468-1253(21)00109-6","volume":"6","author":"S Qin","year":"2021","unstructured":"Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol Jul. 2021;6(7):559\u201368. https:\/\/doi.org\/10.1016\/s2468-1253(21)00109-6.","journal-title":"Lancet Gastroenterol Hepatol Jul"},{"issue":"2","key":"3742_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/s1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after Sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol Feb. 2019;20(2):282\u201396. https:\/\/doi.org\/10.1016\/s1470-2045(18)30937-9.","journal-title":"Lancet Oncol Feb"},{"issue":"10","key":"3742_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1159\/000531316","volume":"101","author":"A Hiraoka","year":"2023","unstructured":"Hiraoka A, Kumada T, Tada T, et al. Lenvatinib as Second-Line treatment after Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma: clinical results show importance of hepatic reserve function. Oncology. 2023;101(10):624\u201333. https:\/\/doi.org\/10.1159\/000531316.","journal-title":"Oncology"},{"key":"3742_CR18","doi-asserted-by":"publisher","unstructured":"Palmer ME, Gile JJ, Storandt MH, et al. Outcomes of patients with advanced hepatocellular carcinoma receiving lenvatinib following immunotherapy: A real world evidence study. Cancers (Basel). 2023;6(19). https:\/\/doi.org\/10.3390\/cancers15194867.","DOI":"10.3390\/cancers15194867"},{"key":"3742_CR19","doi-asserted-by":"publisher","unstructured":"Yano S, Kawaoka T, Yamasaki S, et al. Therapeutic efficacy and safety of lenvatinib after Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Cancers (Basel) Nov. 2023;14(22). https:\/\/doi.org\/10.3390\/cancers15225406.","DOI":"10.3390\/cancers15225406"},{"issue":"3","key":"3742_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.21873\/anticanres.16286","volume":"43","author":"YH Chen","year":"2023","unstructured":"Chen YH, Chen YY, Wang JH, Hung CH. Efficacy and safety of lenvatinib after progression on First-line Atezolizumab plus bevacizumab treatment in advanced hepatocellular carcinoma patients. Anticancer Res Mar. 2023;43(3):1377\u201384. https:\/\/doi.org\/10.21873\/anticanres.16286.","journal-title":"Anticancer Res Mar"},{"key":"3742_CR21","doi-asserted-by":"publisher","first-page":"175883592311894","DOI":"10.1177\/17588359231189425","volume":"15","author":"M Falette-Puisieux","year":"2023","unstructured":"Falette-Puisieux M, Nault JC, Bouattour M, et al. Beyond Atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting. Ther Adv Med Oncol. 2023;15:17588359231189425. https:\/\/doi.org\/10.1177\/17588359231189425.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"3742_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.21037\/atm-22-6614","volume":"31","author":"T Yan","year":"2023","unstructured":"Yan T, Huang C, Peng C, et al. A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma. Ann Transl Med Jan. 2023;31(2):109. https:\/\/doi.org\/10.21037\/atm-22-6614.","journal-title":"Ann Transl Med Jan"},{"issue":"2","key":"3742_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.21037\/hbsn-22-469","volume":"10","author":"DY Xie","year":"2023","unstructured":"Xie DY, Zhu K, Ren ZG, Zhou J, Fan J, Gao Q. A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr Apr. 2023;10(2):216\u201328. https:\/\/doi.org\/10.21037\/hbsn-22-469.","journal-title":"Hepatobiliary Surg Nutr Apr"},{"key":"3742_CR24","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2147\/ott.S383685","volume":"15","author":"K Liu","year":"2022","unstructured":"Liu K, Wu J, Xu Y, Li D, Huang S, Mao Y. Efficacy and safety of regorafenib with or without PD-1 inhibitors as Second-Line therapy for advanced hepatocellular carcinoma in Real-World clinical practice. Onco Targets Ther. 2022;15:1079\u201394. https:\/\/doi.org\/10.2147\/ott.S383685.","journal-title":"Onco Targets Ther"},{"issue":"10408","key":"3742_CR25","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/s0140-6736(23)00961-3","volume":"30","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, et al. Camrelizumab plus Rivoceranib versus Sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet Sep. 2023;30(10408):1133\u201346. https:\/\/doi.org\/10.1016\/s0140-6736(23)00961-3.","journal-title":"Lancet Sep"},{"issue":"4","key":"3742_CR26","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.Ccr-20-2571","volume":"15","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, Open-label, phase II trial. Clin Cancer Res Feb. 2021;15(4):1003\u201311. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2571.","journal-title":"Clin Cancer Res Feb"},{"issue":"7","key":"3742_CR27","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/s1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus Sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol Jul. 2021;22(7):977\u201390. https:\/\/doi.org\/10.1016\/s1470-2045(21)00252-7.","journal-title":"Lancet Oncol Jul"},{"issue":"4","key":"3742_CR28","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol Apr. 2022;76(4):862\u201373. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030.","journal-title":"J Hepatol Apr"},{"issue":"8","key":"3742_CR29","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid Aug. 2022;1(8):EVIDoa2100070. https:\/\/doi.org\/10.1056\/EVIDoa2100070.","journal-title":"NEJM Evid Aug"},{"issue":"10126","key":"3742_CR30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(18)30207-1","volume":"24","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet Mar. 2018;24(10126):1163\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(18)30207-1.","journal-title":"Lancet Mar"},{"issue":"6","key":"3742_CR31","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.dld.2023.11.027","volume":"56","author":"X Li","year":"2024","unstructured":"Li X, Wang X, Bai T, et al. Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study. Dig Liver Dis Jun. 2024;56(6):1078\u201386. https:\/\/doi.org\/10.1016\/j.dld.2023.11.027.","journal-title":"Dig Liver Dis Jun"},{"issue":"5","key":"3742_CR32","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.21037\/tcr-24-93","volume":"31","author":"W Zhao","year":"2024","unstructured":"Zhao W, Liu C, Wu Y, et al. Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience. Transl Cancer Res May. 2024;31(5):2315\u201331. https:\/\/doi.org\/10.21037\/tcr-24-93.","journal-title":"Transl Cancer Res May"},{"issue":"4","key":"3742_CR33","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/liv.15831","volume":"44","author":"M Cai","year":"2024","unstructured":"Cai M, Huang W, Liang W, et al. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study. Liver Int Apr. 2024;44(4):920\u201330. https:\/\/doi.org\/10.1111\/liv.15831.","journal-title":"Liver Int Apr"},{"key":"3742_CR34","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2147\/jhc.S428980","volume":"10","author":"SQ Li","year":"2023","unstructured":"Li SQ, Wu JY, Wu JY, et al. Transarterial chemoembolization plus lenvatinib and PD-1 inhibitors for hepatocellular carcinoma with main trunk portal vein tumor thrombus: A multicenter retrospective study. J Hepatocell Carcinoma. 2023;10:1799\u2013811. https:\/\/doi.org\/10.2147\/jhc.S428980.","journal-title":"J Hepatocell Carcinoma"},{"issue":"2","key":"3742_CR35","doi-asserted-by":"publisher","first-page":"101232","DOI":"10.1016\/j.jhepr.2024.101232","volume":"7","author":"M Wu","year":"2025","unstructured":"Wu M, Fulgenzi CAM, D\u2019Alessio A, et al. Second-line treatment patterns and outcomes in advanced HCC after progression on Atezolizumab\/bevacizumab. JHEP Rep Feb. 2025;7(2):101232. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101232.","journal-title":"JHEP Rep Feb"},{"key":"3742_CR36","doi-asserted-by":"publisher","unstructured":"Terashima T, Kido H, Takata N, et al. Phase II study of Atezolizumab and bevacizumab combination therapy for patients with advanced hepatocellular carcinoma previously treated with lenvatinib. Cancers (Basel) Jan. 2025;16(2). https:\/\/doi.org\/10.3390\/cancers17020278.","DOI":"10.3390\/cancers17020278"},{"key":"3742_CR37","doi-asserted-by":"publisher","unstructured":"Yu Z, Leng B, You R, Diao L, Xu Q, Yin G. Comparative efficacy of lenvatinib plus immunotherapy and regorafenib plus immunotherapy after lenvatinib failure for advanced hepatocellular carcinoma: A retrospective study. Drugs Real World Outcomes Jan. 2025;20. https:\/\/doi.org\/10.1007\/s40801-024-00480-9.","DOI":"10.1007\/s40801-024-00480-9"},{"key":"3742_CR38","doi-asserted-by":"publisher","first-page":"1495321","DOI":"10.3389\/fonc.2024.1495321","volume":"14","author":"JY Lee","year":"2024","unstructured":"Lee JY, Lee J, Kim S, et al. Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma. Front Oncol. 2024;14:1495321. https:\/\/doi.org\/10.3389\/fonc.2024.1495321.","journal-title":"Front Oncol"},{"issue":"2","key":"3742_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000512781","volume":"10","author":"C Yoo","year":"2021","unstructured":"Yoo C, Kim JH, Ryu MH, et al. Clinical outcomes with multikinase inhibitors after progression on First-Line Atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational multicenter retrospective study. Liver Cancer Apr. 2021;10(2):107\u201314. https:\/\/doi.org\/10.1159\/000512781.","journal-title":"Liver Cancer Apr"},{"issue":"12","key":"3742_CR40","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1093\/oncolo\/oyac183","volume":"9","author":"RS Finn","year":"2022","unstructured":"Finn RS, Yau T, Hsu CH, et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha Fetoprotein following Non-Sorafenib systemic therapy: an expansion cohort of REACH-2. Oncologist Dec. 2022;9(12):e938\u201348. https:\/\/doi.org\/10.1093\/oncolo\/oyac183.","journal-title":"Oncologist Dec"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03742-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03742-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03742-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:51:20Z","timestamp":1741848680000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03742-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3742"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03742-0","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University. Written informed consent was obtained from individual or guardian participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}